000132624 001__ 132624
000132624 005__ 20240229105023.0
000132624 0247_ $$2doi$$a10.1016/j.clcc.2017.09.002
000132624 0247_ $$2pmid$$apmid:29074354
000132624 0247_ $$2ISSN$$a1533-0028
000132624 0247_ $$2ISSN$$a1938-0674
000132624 037__ $$aDKFZ-2018-00284
000132624 041__ $$aeng
000132624 082__ $$a610
000132624 1001_ $$0P:(DE-HGF)0$$aBabaei, Masoud$$b0$$eFirst author
000132624 245__ $$aNeoadjuvant Therapy in Rectal Cancer Patients With Clinical Stage II to III Across European Countries: Variations and Outcomes.
000132624 260__ $$aDallas, Tex.$$bCancer Information Group$$c2018
000132624 264_1 $$2Crossref$$3print$$bElsevier BV$$c2018-03-01
000132624 264_1 $$2Crossref$$3print$$bElsevier BV$$c2018-03-01
000132624 3367_ $$2DRIVER$$aarticle
000132624 3367_ $$2DataCite$$aOutput Types/Journal article
000132624 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1659445581_15545
000132624 3367_ $$2BibTeX$$aARTICLE
000132624 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000132624 3367_ $$00$$2EndNote$$aJournal Article
000132624 520__ $$aNeoadjuvant therapy improves survival of patients with clinical stage II and III rectal cancer in clinical trials. In this study, we investigated the administration of neoadjuvant radiotherapy (neo-RT) and neoadjuvant chemoradiotherapy (neo-CRT) and its association with survival in resected patients in 2 European countries (The Netherlands and Sweden) and at 3 specialist centers.Administration of neoadjuvant treatment (all registries) and overall survival after surgery in The Netherlands and Sweden were assessed. Hazard ratios (HRs) were obtained using Cox regression adjusted for potential confounders.A total of 16,095 rectal cancer patients with clinical stage II and III were eligible for analyses. Large variations in administration of neo-RT and neo-CRT were observed. Elderly patients less often received neo-RT and neo-CRT. Patients with stage III disease received neo-CRT more frequently than neo-RT. Administration of neo-RT versus surgery without neoadjuvant treatment was significantly associated with improved survival in The Netherlands (HR, 0.62; 95% confidence interval [CI], 0.53-0.73) as well as in Sweden (HR, 0.79; 95% CI, 0.69-0.90). Administration of neo-CRT was associated with enhanced survival in The Netherlands (HR, 0.62; 95% CI, 0.50-0.78) but not in Sweden (HR, 0.97; 95% CI, 0.80-1.18). The mortality of patients treated with neo-CRT compared with neo-RT showed inconsistent results in population-based centers.Our results support an association of neo-RT with enhanced survival among stage II and III rectal cancer patients. Comparing neo-CRT with neo-RT, larger variations and inconsistent results with respect to survival were observed across centers.
000132624 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000132624 542__ $$2Crossref$$i2018-03-01$$uhttps://www.elsevier.com/tdm/userlicense/1.0/
000132624 588__ $$aDataset connected to CrossRef, PubMed,
000132624 7001_ $$aJansen, Lina$$b1
000132624 7001_ $$0P:(DE-HGF)0$$aBalavarca, Yesilda$$b2
000132624 7001_ $$aSjövall, Annika$$b3
000132624 7001_ $$aBos, Amanda$$b4
000132624 7001_ $$avan de Velde, Tony$$b5
000132624 7001_ $$aMoreau, Michel$$b6
000132624 7001_ $$aLiberale, Gabriel$$b7
000132624 7001_ $$aGonçalves, Ana Filipa$$b8
000132624 7001_ $$aBento, Maria José$$b9
000132624 7001_ $$0P:(DE-HGF)0$$aUlrich, Cornelia M$$b10
000132624 7001_ $$0P:(DE-He78)01ef71f71b01a3ec3b698653fd43fe86$$aSchrotz-King, Petra$$b11$$udkfz
000132624 7001_ $$aLemmens, Valery$$b12
000132624 7001_ $$aGlimelius, Bengt$$b13
000132624 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b14$$eLast author$$udkfz
000132624 77318 $$2Crossref$$3journal-article$$a10.1016/j.clcc.2017.09.002$$bElsevier BV$$d2018-03-01$$n1$$pe129-e142$$tClinical Colorectal Cancer$$v17$$x1533-0028$$y2018
000132624 773__ $$0PERI:(DE-600)2572502-6$$a10.1016/j.clcc.2017.09.002$$gVol. 17, no. 1, p. e129 - e142$$n1$$pe129-e142$$tClinical colorectal cancer and other gastrointestinal malignancies$$v17$$x1533-0028$$y2018
000132624 909CO $$ooai:inrepo02.dkfz.de:132624$$pVDB
000132624 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000132624 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000132624 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000132624 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)01ef71f71b01a3ec3b698653fd43fe86$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000132624 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000132624 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000132624 9141_ $$y2018
000132624 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCLIN COLORECTAL CANC : 2013
000132624 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000132624 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000132624 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000132624 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000132624 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000132624 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000132624 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000132624 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000132624 9201_ $$0I:(DE-He78)G110-20160331$$kG110$$lPräventive Onkologie$$x1
000132624 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x2
000132624 980__ $$ajournal
000132624 980__ $$aVDB
000132624 980__ $$aI:(DE-He78)C070-20160331
000132624 980__ $$aI:(DE-He78)G110-20160331
000132624 980__ $$aI:(DE-He78)L101-20160331
000132624 980__ $$aUNRESTRICTED
000132624 999C5 $$1Benson$$2Crossref$$9-- missing cx lookup --$$a10.6004/jnccn.2015.0087$$p719 -$$tJ Natl Compr Canc Netw$$v13$$y2015
000132624 999C5 $$1Maringe$$2Crossref$$9-- missing cx lookup --$$a10.3109/0284186X.2013.764008$$p919 -$$tActa Oncol$$v52$$y2013
000132624 999C5 $$1Schmoll$$2Crossref$$9-- missing cx lookup --$$a10.1093/annonc/mds236$$p2479 -$$tAnn Oncol$$v23$$y2012
000132624 999C5 $$1Glimelius$$2Crossref$$9-- missing cx lookup --$$a10.1093/annonc/mdt240$$pvi81 -$$tAnn Oncol$$v24$$y2013
000132624 999C5 $$1Poston$$2Crossref$$9-- missing cx lookup --$$a10.1136/bmj.d6751$$pd6751 -$$tBMJ$$v343$$y2011
000132624 999C5 $$1Valentini$$2Crossref$$9-- missing cx lookup --$$a10.1093/annonc/mdu245$$p1863 -$$tAnn Oncol$$v25$$y2014
000132624 999C5 $$1Glimelius$$2Crossref$$9-- missing cx lookup --$$a10.3109/03009734.2012.658974$$p225 -$$tUps J Med Sci$$v117$$y2012
000132624 999C5 $$1Benson$$2Crossref$$9-- missing cx lookup --$$a10.6004/jnccn.2012.0158$$p1528 -$$tJ Natl Compr Canc Netw$$v10$$y2012
000132624 999C5 $$1van den Broek$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.ejso.2014.09.011$$p1789 -$$tEur J Surg Oncol$$v40$$y2014
000132624 999C5 $$1McVie$$2Crossref$$oMcVie 2012$$y2012
000132624 999C5 $$1Fritz$$2Crossref$$oFritz 2000$$y2000
000132624 999C5 $$1Rahbari$$2Crossref$$9-- missing cx lookup --$$a10.1245/s10434-013-3198-9$$p4169 -$$tAnn Surg Oncol$$v20$$y2013
000132624 999C5 $$1Peev$$2Crossref$$oPeev 2015$$y2015
000132624 999C5 $$1Valentini$$2Crossref$$9-- missing cx lookup --$$a10.3109/0284186X.2010.506884$$p1206 -$$tActa Oncol$$v49$$y2010
000132624 999C5 $$1Wong$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.clon.2010.03.002$$p265 -$$tClin Oncol (R Coll Radiol)$$v22$$y2010
000132624 999C5 $$1McCarthy$$2Crossref$$oMcCarthy 2012$$y2012
000132624 999C5 $$1De Caluwe$$2Crossref$$oDe Caluwe 2013$$y2013
000132624 999C5 $$1Braendengen$$2Crossref$$9-- missing cx lookup --$$a10.1200/JCO.2007.15.3858$$p3687 -$$tJ Clin Oncol$$v26$$y2008
000132624 999C5 $$1Jiang$$2Crossref$$9-- missing cx lookup --$$a10.1093/annonc/mdv331$$p2102 -$$tAnn Oncol$$v26$$y2015
000132624 999C5 $$1Aparicio$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.critrevonc.2008.11.006$$p249 -$$tCrit Rev Oncol Hematol$$v71$$y2009
000132624 999C5 $$1Elliot$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.ejso.2016.05.020$$p1667 -$$tEur J Surg Oncol$$v42$$y2016
000132624 999C5 $$1Pasetto$$2Crossref$$oPasetto 2006$$y2006
000132624 999C5 $$1Bergquist$$2Crossref$$9-- missing cx lookup --$$a10.1007/s00268-015-3319-7$$p447 -$$tWorld J Surg$$v40$$y2016
000132624 999C5 $$1Breugom$$2Crossref$$9-- missing cx lookup --$$a10.1016/S1470-2045(14)71199-4$$p200 -$$tLancet Oncol$$v16$$y2015
000132624 999C5 $$1Bujko$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.ejso.2015.03.233$$p713 -$$tEur J Surg Oncol$$v41$$y2015
000132624 999C5 $$1Poulsen$$2Crossref$$9-- missing cx lookup --$$a10.3109/0284186X.2014.993768$$p437 -$$tActa Oncol$$v54$$y2015
000132624 999C5 $$1van de Velde$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.ejca.2013.06.048$$p1.e1 -$$tEur J Cancer$$v50$$y2014